Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Establishment and Characterisation by Expression Microarray of Patient-Derived Xenograft Panel of Human Pancreatic Adenocarcinoma Patients.

Roche S, O'Neill F, Murphy J, Swan N, Meiller J, Conlon NT, Geoghegan J, Conlon K, McDermott R, Rahman R, Toomey S, Straubinger NL, Straubinger RM, O'Connor R, McVey G, Moriarty M, Clynes M.

Int J Mol Sci. 2020 Jan 31;21(3). pii: E962. doi: 10.3390/ijms21030962.

2.

Repurposing of Cetuximab in antibody-directed chemotherapy-loaded nanoparticles in EGFR therapy-resistant pancreatic tumours.

McDaid WJ, Greene MK, Johnston MC, Pollheimer E, Smyth P, McLaughlin K, Van Schaeybroeck S, Straubinger RM, Longley DB, Scott CJ.

Nanoscale. 2019 Nov 14;11(42):20261-20273. doi: 10.1039/c9nr07257h. Epub 2019 Oct 18.

PMID:
31626255
3.

Tumor Priming by SMO Inhibition Enhances Antibody Delivery and Efficacy in a Pancreatic Ductal Adenocarcinoma Model.

Wang J, Chan DKW, Sen A, Ma WW, Straubinger RM.

Mol Cancer Ther. 2019 Nov;18(11):2074-2084. doi: 10.1158/1535-7163.MCT-18-0354. Epub 2019 Jul 30.

PMID:
31363010
4.

Pharmacodynamic Drug-Drug Interactions.

Niu J, Straubinger RM, Mager DE.

Clin Pharmacol Ther. 2019 Jun;105(6):1395-1406. doi: 10.1002/cpt.1434. Epub 2019 Apr 26.

PMID:
30912119
5.

Pharmacokinetics and pharmacodynamics of liposomal chemophototherapy with short drug-light intervals.

Luo D, Carter KA, Molins EAG, Straubinger NL, Geng J, Shao S, Jusko WJ, Straubinger RM, Lovell JF.

J Control Release. 2019 Mar 10;297:39-47. doi: 10.1016/j.jconrel.2019.01.030. Epub 2019 Jan 23.

PMID:
30684512
6.

A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients.

Ma WW, Xie H, Fetterly G, Pitzonka L, Whitworth A, LeVea C, Wilton J, Mantione K, Schihl S, Dy GK, Boland P, Iyer R, Tan W, Brady W, Straubinger RM, Adjei AA.

Am J Clin Oncol. 2019 Feb;42(2):184-189. doi: 10.1097/COC.0000000000000492.

7.

A Comparative Quantitative LC-MS/MS Profiling Analysis of Human Pancreatic Adenocarcinoma, Adjacent-Normal Tissue, and Patient-Derived Tumour Xenografts.

Coleman O, Henry M, O'Neill F, Roche S, Swan N, Boyle L, Murphy J, Meiller J, Conlon NT, Geoghegan J, Conlon KC, Lynch V, Straubinger NL, Straubinger RM, McVey G, Moriarty M, Meleady P, Clynes M.

Proteomes. 2018 Nov 6;6(4). pii: E45. doi: 10.3390/proteomes6040045.

8.

Multi-Scale Network Model Supported by Proteomics for Analysis of Combined Gemcitabine and Birinapant Effects in Pancreatic Cancer Cells.

Zhu X, Shen X, Qu J, Straubinger RM, Jusko WJ.

CPT Pharmacometrics Syst Pharmacol. 2018 Sep;7(9):549-561. doi: 10.1002/psp4.12320. Epub 2018 Aug 9.

9.

Physiologically-based pharmacokinetic and pharmacodynamic models for gemcitabine and birinapant in pancreatic cancer xenografts.

Zhu X, Trueman S, Straubinger RM, Jusko WJ.

J Pharmacokinet Pharmacodyn. 2018 Oct;45(5):733-746. doi: 10.1007/s10928-018-9603-z. Epub 2018 Aug 1.

10.

Comparison of the composition and in vitro activity of polymyxin B products.

Diep JK, Covelli J, Sharma R, Ruszaj DM, Kaye KS, Li J, Straubinger RM, Rao GG.

Int J Antimicrob Agents. 2018 Sep;52(3):365-371. doi: 10.1016/j.ijantimicag.2018.05.014. Epub 2018 May 25.

PMID:
29807163
11.

Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer.

Camblin AJ, Pace EA, Adams S, Curley MD, Rimkunas V, Nie L, Tan G, Bloom T, Iadevaia S, Baum J, Minx C, Czibere A, Louis CU, Drummond DC, Nielsen UB, Schoeberl B, Pipas JM, Straubinger RM, Askoxylakis V, Lugovskoy AA.

Clin Cancer Res. 2018 Jun 15;24(12):2873-2885. doi: 10.1158/1078-0432.CCR-17-2262. Epub 2018 Mar 16.

12.

Development and Evaluation of Tri-Functional Immunoliposomes for the Treatment of HER2 Positive Breast Cancer.

Vaidya T, Straubinger RM, Ait-Oudhia S.

Pharm Res. 2018 Mar 13;35(5):95. doi: 10.1007/s11095-018-2365-x.

PMID:
29536232
13.

Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells.

Zhu X, Shen X, Qu J, Straubinger RM, Jusko WJ.

Front Pharmacol. 2018 Feb 19;9:84. doi: 10.3389/fphar.2018.00084. eCollection 2018.

14.

Temporal Effects of Combined Birinapant and Paclitaxel on Pancreatic Cancer Cells Investigated via Large-Scale, Ion-Current-Based Quantitative Proteomics (IonStar).

Wang X, Niu J, Li J, Shen X, Shen S, Straubinger RM, Qu J.

Mol Cell Proteomics. 2018 Apr;17(4):655-671. doi: 10.1074/mcp.RA117.000519. Epub 2018 Jan 22.

15.

Flow arrest intra-arterial delivery of small TAT-decorated and neutral micelles to gliomas.

Nguyen J, Hossain SS, Cooke JRN, Ellis JA, Deci MB, Emala CW, Bruce JN, Bigio IJ, Straubinger RM, Joshi S.

J Neurooncol. 2017 May;133(1):77-85. doi: 10.1007/s11060-017-2429-5. Epub 2017 Apr 18.

PMID:
28421460
16.

Quantitative proteomic profiling of paired cancerous and normal colon epithelial cells isolated freshly from colorectal cancer patients.

Tu C, Mojica W, Straubinger RM, Li J, Shen S, Qu M, Nie L, Roberts R, An B, Qu J.

Proteomics Clin Appl. 2017 May;11(5-6). doi: 10.1002/prca.201600155. Epub 2017 Jan 20.

17.

Pharmacodynamic Modeling of Cell Cycle Effects for Gemcitabine and Trabectedin Combinations in Pancreatic Cancer Cells.

Miao X, Koch G, Ait-Oudhia S, Straubinger RM, Jusko WJ.

Front Pharmacol. 2016 Nov 15;7:421. eCollection 2016.

18.

Liposome size and charge optimization for intraarterial delivery to gliomas.

Joshi S, Cooke JR, Chan DK, Ellis JA, Hossain SS, Singh-Moon RP, Wang M, Bigio IJ, Bruce JN, Straubinger RM.

Drug Deliv Transl Res. 2016 Jun;6(3):225-33. doi: 10.1007/s13346-016-0294-y.

19.

Large-Scale, Ion-Current-Based Proteomic Investigation of the Rat Striatal Proteome in a Model of Short- and Long-Term Cocaine Withdrawal.

Shen S, Jiang X, Li J, Straubinger RM, Suarez M, Tu C, Duan X, Thompson AC, Qu J.

J Proteome Res. 2016 May 6;15(5):1702-16. doi: 10.1021/acs.jproteome.6b00137. Epub 2016 Apr 11.

20.

Cationizable lipid micelles as vehicles for intraarterial glioma treatment.

Nguyen J, Cooke JRN, Ellis JA, Deci M, Emala CW, Bruce JN, Bigio IJ, Straubinger RM, Joshi S.

J Neurooncol. 2016 May;128(1):21-28. doi: 10.1007/s11060-016-2088-y. Epub 2016 Feb 22.

21.

Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cells.

Miao X, Koch G, Straubinger RM, Jusko WJ.

Cancer Chemother Pharmacol. 2016 Jan;77(1):181-93. doi: 10.1007/s00280-015-2907-4. Epub 2015 Nov 25.

22.

Tumor-Priming Smoothened Inhibitor Enhances Deposition and Efficacy of Cytotoxic Nanoparticles in a Pancreatic Cancer Model.

Roy Chaudhuri T, Straubinger NL, Pitoniak RF, Hylander BL, Repasky EA, Ma WW, Straubinger RM.

Mol Cancer Ther. 2016 Jan;15(1):84-93. doi: 10.1158/1535-7163.MCT-15-0602. Epub 2015 Oct 29.

23.

Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells.

Zhu X, Straubinger RM, Jusko WJ.

J Pharmacokinet Pharmacodyn. 2015 Oct;42(5):477-96. doi: 10.1007/s10928-015-9429-x. Epub 2015 Aug 8.

24.

Cerebral hypoperfusion-assisted intra-arterial deposition of liposomes in normal and glioma-bearing rats.

Joshi S, Singh-Moon RP, Ellis JA, Chaudhuri DB, Wang M, Reif R, Bruce JN, Bigio IJ, Straubinger RM.

Neurosurgery. 2015 Jan;76(1):92-100. doi: 10.1227/NEU.0000000000000552.

25.

Cationic surface charge enhances early regional deposition of liposomes after intracarotid injection.

Joshi S, Singh-Moon R, Wang M, Chaudhuri DB, Ellis JA, Bruce JN, Bigio IJ, Straubinger RM.

J Neurooncol. 2014 Dec;120(3):489-97. doi: 10.1007/s11060-014-1584-1. Epub 2014 Sep 7.

26.

Transient cerebral hypoperfusion assisted intraarterial cationic liposome delivery to brain tissue.

Joshi S, Singh-Moon RP, Wang M, Chaudhuri DB, Holcomb M, Straubinger NL, Bruce JN, Bigio IJ, Straubinger RM.

J Neurooncol. 2014 May;118(1):73-82. doi: 10.1007/s11060-014-1421-6. Epub 2014 Mar 25.

27.

Application of pharmacokinetic and pharmacodynamic analysis to the development of liposomal formulations for oncology.

Ait-Oudhia S, Mager DE, Straubinger RM.

Pharmaceutics. 2014 Mar 18;6(1):137-74. doi: 10.3390/pharmaceutics6010137.

28.

Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models.

Zhang H, Hylander BL, LeVea C, Repasky EA, Straubinger RM, Adjei AA, Ma WW.

Br J Cancer. 2014 Jan 21;110(2):320-9. doi: 10.1038/bjc.2013.754. Epub 2013 Dec 10.

29.

Pharmacodynamic modeling of cell cycle and apoptotic effects of gemcitabine on pancreatic adenocarcinoma cells.

Hamed SS, Straubinger RM, Jusko WJ.

Cancer Chemother Pharmacol. 2013 Sep;72(3):553-63. doi: 10.1007/s00280-013-2226-6. Epub 2013 Jul 9.

30.

Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice.

Pawaskar DK, Straubinger RM, Fetterly GJ, Hylander BH, Repasky EA, Ma WW, Jusko WJ.

Cancer Chemother Pharmacol. 2013 May;71(5):1231-40. doi: 10.1007/s00280-013-2117-x. Epub 2013 Mar 3.

31.

Physiologically based pharmacokinetic models for everolimus and sorafenib in mice.

Pawaskar DK, Straubinger RM, Fetterly GJ, Hylander BH, Repasky EA, Ma WW, Jusko WJ.

Cancer Chemother Pharmacol. 2013 May;71(5):1219-29. doi: 10.1007/s00280-013-2116-y. Epub 2013 Mar 3.

32.

Determination of the Proteomic Response to Lapatinib Treatment using a comprehensive and reproducible ion-current-based proteomics strategy.

O'Connell K, Li J, Engler F, Hennessy K, O'Neill F, Straubinger RM, Qu J, O'Connor R.

J Proteom Genom Res. 2013;1(3):27-42. doi: 10.14302/issn.2326-0793.jpgr-13-257. Epub 2013 Sep 8.

33.

Interactions of everolimus and sorafenib in whole blood lymphocyte proliferation.

Pawaskar DK, Straubinger RM, Fetterly GJ, Ma WW, Jusko WJ.

Pharm Res. 2013 Mar;30(3):707-13. doi: 10.1007/s11095-012-0909-z. Epub 2012 Nov 14.

34.

Systems pharmacological analysis of paclitaxel-mediated tumor priming that enhances nanocarrier deposition and efficacy.

Ait-Oudhia S, Straubinger RM, Mager DE.

J Pharmacol Exp Ther. 2013 Jan;344(1):103-12. doi: 10.1124/jpet.112.199109. Epub 2012 Oct 31. Erratum in: J Pharmacol Exp Ther. 2018 Aug;366(2):365-366.

35.

Interactions of everolimus and sorafenib in pancreatic cancer cells.

Pawaskar DK, Straubinger RM, Fetterly GJ, Ma WW, Jusko WJ.

AAPS J. 2013 Jan;15(1):78-84. doi: 10.1208/s12248-012-9417-7. Epub 2012 Oct 9.

36.

Mechanisms of tumor vascular priming by a nanoparticulate doxorubicin formulation.

Roy Chaudhuri T, Arnold RD, Yang J, Turowski SG, Qu Y, Spernyak JA, Mazurchuk R, Mager DE, Straubinger RM.

Pharm Res. 2012 Dec;29(12):3312-24. doi: 10.1007/s11095-012-0823-4. Epub 2012 Jul 14.

37.

Meta-analysis of nanoparticulate paclitaxel delivery system pharmacokinetics and model prediction of associated neutropenia.

Ait-Oudhia S, Straubinger RM, Mager DE.

Pharm Res. 2012 Oct;29(10):2833-44. doi: 10.1007/s11095-012-0775-8. Epub 2012 May 17.

PMID:
22588463
38.

Physicochemical properties of epidermal growth factor receptor inhibitors and development of a nanoliposomal formulation of gefitinib.

Trummer BJ, Iyer V, Balu-Iyer SV, O'Connor R, Straubinger RM.

J Pharm Sci. 2012 Aug;101(8):2763-76. doi: 10.1002/jps.23180. Epub 2012 May 11.

39.

Combinatorial chemotherapeutic efficacy in non-Hodgkin lymphoma can be predicted by a signaling model of CD20 pharmacodynamics.

Harrold JM, Straubinger RM, Mager DE.

Cancer Res. 2012 Apr 1;72(7):1632-41. doi: 10.1158/0008-5472.CAN-11-2432. Epub 2012 Feb 20.

40.

Downregulation of CD40 signal and induction of TGF-β by phosphatidylinositol mediates reduction in immunogenicity against recombinant human Factor VIII.

Gaitonde P, Peng A, Straubinger RM, Bankert RB, Balu-Iyer SV.

J Pharm Sci. 2012 Jan;101(1):48-55. doi: 10.1002/jps.22746. Epub 2011 Sep 23.

41.

Phosphatidylserine reduces immune response against human recombinant Factor VIII in Hemophilia A mice by regulation of dendritic cell function.

Gaitonde P, Peng A, Straubinger RM, Bankert RB, Balu-Iyer SV.

Clin Immunol. 2011 Feb;138(2):135-45. doi: 10.1016/j.clim.2010.10.006. Epub 2010 Nov 20.

42.

Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a mice.

Peng A, Straubinger RM, Balu-Iyer SV.

AAPS J. 2010 Sep;12(3):473-81. doi: 10.1208/s12248-010-9207-z. Epub 2010 Jun 2.

43.

A rapid, reproducible, on-the-fly orthogonal array optimization method for targeted protein quantification by LC/MS and its application for accurate and sensitive quantification of carbonyl reductases in human liver.

Cao J, Gonzalez-Covarrubias V, Straubinger RM, Wang H, Duan X, Yu H, Qu J, Blanco JG.

Anal Chem. 2010 Apr 1;82(7):2680-9. doi: 10.1021/ac902314m. Erratum in: Anal Chem. 2010 Sep 15;82(18):7861. Covarrubias, Vanessa M [corrected to Gonzalez-Covarrubias., Vanessa].

44.

Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systems.

Yang J, Mager DE, Straubinger RM.

AAPS J. 2010 Mar;12(1):1-10. doi: 10.1208/s12248-009-9155-7. Epub 2009 Nov 10.

45.

Differential pharmacodynamic effects of paclitaxel formulations in an intracranial rat brain tumor model.

Zhou R, Mazurchuk RV, Tamburlin JH, Harrold JM, Mager DE, Straubinger RM.

J Pharmacol Exp Ther. 2010 Feb;332(2):479-88. doi: 10.1124/jpet.109.160044. Epub 2009 Oct 27.

47.

Accurate localization and relative quantification of arginine methylation using nanoflow liquid chromatography coupled to electron transfer dissociation and orbitrap mass spectrometry.

Wang H, Straubinger RM, Aletta JM, Cao J, Duan X, Yu H, Qu J.

J Am Soc Mass Spectrom. 2009 Mar;20(3):507-19. doi: 10.1016/j.jasms.2008.11.008. Epub 2008 Nov 21.

48.
49.

Ultra-sensitive quantification of paclitaxel using selective solid-phase extraction in conjunction with reversed-phase capillary liquid chromatography/tandem mass spectrometry.

Yu H, Straubinger RM, Cao J, Wang H, Qu J.

J Chromatogr A. 2008 Nov 14;1210(2):160-7. doi: 10.1016/j.chroma.2008.09.052. Epub 2008 Sep 19.

50.

Passive transfer of polyethylene glycol to liposomal-recombinant human FVIII enhances its efficacy in a murine model for hemophilia A.

Ramani K, Purohit V, Miclea R, Gaitonde P, Straubinger RM, Balu-Iyer SV.

J Pharm Sci. 2008 Sep;97(9):3753-64. doi: 10.1002/jps.21266.

Supplemental Content

Loading ...
Support Center